Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data
Capricor Therapeutics filed a BLA for deramiocel, showing promising results in slowing cardiac dysfunction in DMD ...
来自MSN1 个月
Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade
Capricor Therapeutics (CAPR) closed the last trading session at $13.47, gaining 7.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated ...
On Tuesday, the FDA accepted for review Capricor Therapeutics Inc’s (NASDAQ:CAPR) Biologics License Application for ...
ETF Daily News17 天
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50
Several research firms recently commented on CAPR. Cantor Fitzgerald upped their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a ...
Nasdaq1 个月
Noteworthy Tuesday Option Activity: CAPR, WWD, MCD
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Capricor Therapeutics Inc (Symbol: CAPR), where a total volume of 5,091 ...
Benzinga.com4 天
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated ...
On Tuesday, the FDA accepted for review Capricor Therapeutics Inc’s CAPR Biologics License Application ... arrhythmias, and heart failure. Additionally, the FDA granted the BLA Priority Review ...